phase IV clinical studies received by ClinicalTrials.gov between 2004-2014
收藏官方服务：
资源简介：
This dataset was downloaded from the Internet at March 18, 2015
应用场景：
创建时间：
2016-01-01
相关数据集
Required Clinical Trial After Approval Database
This dataset is the main file to construct the FDA (U.S. Food and Drug Administration) Postmarketing Requirements and Commitments searchable database. Postmarketing requirements refers to studies requ
www.johnsnowlabs.com70
Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis
Background Clinical studies for assessing the effectiveness and safety in a premarketing setting are conducted under time and cost constraints. In recent years, postmarketing data analysis has been gi
NIAID Data Ecosystem60
Dataset from A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants
This is double-blind, randomized, sequential, two part study. Part 1 is a 3 periods, fixed-sequence study and will be conducted to evaluate the pharmacokinetics, safety, and tolerability of the gepo
NIAID Data Ecosystem30
Supplementary Material for: Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan
Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiv
Figshare2022-11-18 更新60
Dataset from A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban
The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat
NIAID Data Ecosystem30
